Gantacurium chloride
| Clinical data | |
|---|---|
| Routes of administration | IV |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Protein binding | unknown |
| Metabolism | rapid inactivation by endogenous cysteine adduct formation followed by slow ester hydrolysis |
| Elimination half-life | unknown |
| Excretion | renal / hepatic |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C53H69Cl3N2O14 |
| Molar mass | 1064.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Gantacurium chloride (formerly recognized as GW280430A and as AV430A) is a new experimental neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in surgical anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Gantacurium is no longer in clinical development.